GET DAILY SIGNALSTransMedics Group (TMDX) Delivers Record Q3 Revenue and Raises Full-Year Guidance
Key Takeaways
- TransMedics delivered record third-quarter revenue of roughly $203 million, up 41% year over year and above consensus estimates.
- Adjusted earnings per share of $0.51 exceeded expectations, though GAAP net income declined as research, clinical, and interest expenses climbed.
- Management raised full-year 2026 revenue guidance to $764–$774 million, implying approximately 26%–28% growth.
- Shares are roughly 9% higher over the trailing 30 days despite a volatile path that included a late-October sell-off followed by a sharp post-earnings rebound.
- Gross margin pressure persists as the company invests in OCS Kidney, next-generation OCS, and its ENHANCE and DENOVO clinical programs.
- The FDA cleared key trial amendments, and the company won its first European transplant logistics tender in Italy, supporting a 2027 catalyst pipeline.
- For additional detail, explore TransMedics Price Targets, Earnings, and Forecast pages.
- Investors seeking systematic ideas can also explore Trending AI Robots, which highlights top-performing AI-driven strategies.
Current Market Snapshot
TransMedics Group (NASDAQ: TMDX) sits at the intersection of medical technology and organ transplantation, a niche that has drawn steady investor attention because of its limited competition and large addressable market. Over the trailing 30 days, the stock has moved from about $81 to roughly $88, but that headline masks meaningful volatility. Shares weakened through much of October before rallying sharply after the company reported third-quarter results, as revenue reaccelerated and guidance was raised. The stock trades with above-average volatility typical of high-growth medtech names, with sentiment closely tied to quarterly case volumes, margin trajectory, and clinical-trial milestones rather than broad market rotation alone. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
TransMedics Group (TMDX) Business Overview and Competitive Position
TransMedics Group is a commercial-stage medical technology company focused on transforming organ transplant therapy for patients with end-stage heart, lung, and liver failure. Its core platform, the Organ Care System (OCS), is a portable system that uses warm perfusion to keep donor organs functioning in near-physiologic conditions outside the body, replacing traditional cold storage. The OCS is the only FDA-approved portable warm-perfusion platform covering heart, lung, and liver transplants, which gives the company a differentiated position in a market with limited direct competition.
Beyond the device itself, TransMedics operates the National OCS Program (NOP), a turnkey service offering outsourced organ procurement, perfusion management, and transplant logistics, including aviation transport through its PAD Aviation business. This integrated model allows the company to capture both product and service revenue, deepening its relationship with transplant centers while expanding its total addressable opportunity. Investors follow TMDX for its combination of organic case-volume growth, international expansion, and a clinical pipeline aimed at broadening indications in heart and lung transplantation.
Recent Developments Driving TMDX
The most significant recent catalyst was the company's third-quarter 2026 earnings release, which showed total revenue of about $203 million, up 41% year over year and the strongest quarter in the company's history. Product revenue rose 29% to roughly $113 million, while service revenue climbed 60% to about $90 million. International revenue increased 82%, and liver and heart case volumes grew sequentially despite a 6% decline in overall U.S. deceased donor volume, signaling market-share gains.
Adjusted earnings per share of $0.51 beat consensus estimates by a wide margin, and management raised full-year 2026 revenue guidance to $764–$774 million. However, the quarter also highlighted the cost of growth: gross margin slipped to 58.5%, research and development spending nearly doubled, and interest expense rose as new lease obligations were added. GAAP net income fell year over year even as operating income grew. On the clinical front, the FDA approved protocol amendments adding the company's CHOPS system as a control arm in the ENHANCE Heart Part B and DENOVO Lung trials, and TransMedics won its first European transplant logistics tender in Italy. Analyst responses were mixed, with Hold ratings from firms including Oppenheimer and J.P. Morgan alongside a Buy rating from Canaccord Genuity. From what I see, the clinical updates add meaningful visibility into the 2027 pipeline.
2026 Outlook and What Investors Should Watch
Looking ahead, several factors will shape the TMDX investment case. The ENHANCE Heart Part B and DENOVO Lung programs are expected to become meaningful catalysts beginning in early 2027, with the potential to expand the company's addressable heart and lung transplant populations. OCS Kidney development is progressing toward clinical testing in 2027, representing a longer-term growth opportunity. International expansion, supported by aviation infrastructure and logistics hubs in Europe, is another key driver.
On the financial side, investors will monitor whether revenue growth can translate into margin improvement as the company works through its investment cycle. Management has guided to adjusted operating margins of 12.5%–14% for 2026 and has not yet reiterated longer-term margin targets. Rising interest expense, service gross-margin normalization, and the timing of clinical-trial revenue are additional considerations. Macroeconomic and regulatory factors affecting transplant volumes, donor supply, and reimbursement also remain relevant to the outlook. I’m watching this closely as the margin trajectory could determine how the multiple holds up into next year.
Exploring Systematic Trading Approaches
In my view, complementing fundamental analysis with data-driven tools can provide useful perspective on names like TMDX. I recently reviewed Tickeron’s AI Trading Bots to compare automated strategies that monitor similar medtech names and highlight performance across different timeframes. This approach offers a practical way to evaluate systematic signals alongside traditional research without replacing individual judgment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for TMDX turns positive, indicating new upward trend
TMDX saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned positive. In 77 of the 89 cases, the stock moved higher in the following days. The odds of a move higher are at 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for TMDX just turned positive on November 04, 2026. Looking at past instances where TMDX's MACD turned positive, the stock continued to rise in 39 of 48 cases over the following month. The odds of a continued upward trend are 81%.
TMDX moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +9.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where TMDX advanced for three days, in 254 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TMDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
TMDX broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for TMDX entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 28 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. TMDX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 64 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.906) is normal, around the industry mean (4.142). P/E Ratio (19.829) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.709) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (5.033) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 93 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of a proprietary system for preserving human organs for transplant
Industry MedicalNursingServices
Advertisement